Efficacy of Deep TMS with the H1 Coil for Anxious Depression
Open Access
- 15 February 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1015
Abstract
(1) Background: While the therapeutic efficacy of Transcranial Magnetic Stimulation (TMS) for major depressive disorder (MDD) is well established, less is known about the technique’s efficacy for treating comorbid anxiety. (2) Methods: Data were retrospectively analyzed from randomized controlled trials (RCTs) that used Deep TMS with the H1 Coil for MDD treatment. The primary endpoint was the difference relative to sham treatment following 4 weeks of stimulation. The effect size was compared to literature values for superficial TMS and medication treatments. (3) Results: In the pivotal RCT, active Deep TMS compared with sham treatment showed significantly larger improvements in anxiety score (effect size = 0.34, p = 0.03 (FDR)) which were sustained until 16 weeks (effect size = 0.35, p = 0.04). The pooled effect size between all the RCTs was 0.55, which compares favorably to alternative treatments. A direct comparison to Figure-8 Coil treatment indicated that treatment with the H1 Coil was significantly more effective (p = 0.042). In contrast to previously reported studies using superficial TMS and medication for which anxiety has been shown to be a negative predictor of effectiveness, higher baseline anxiety was found to be predictive of successful outcome for the H1-Coil treatment. (4) Conclusions: Deep TMS is effective in treating comorbid anxiety in MDD and, unlike alternative treatments, the outcome does not appear to be adversely affected by high baseline anxiety levels.Keywords
This publication has 41 references indexed in Scilit:
- Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitorsEuropean Neuropsychopharmacology, 2012
- Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Acute Treatment of Medication-Resistant DepressionAmerican Journal of Psychiatry, 2011
- What is the genetic relationship between anxiety and depression?American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2008
- Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D ReportAmerican Journal of Psychiatry, 2008
- Clinical Factors Associated With Treatment Resistance in Major Depressive DisorderThe Journal of Clinical Psychiatry, 2007
- Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority studyCurrent Medical Research and Opinion, 2007
- Escitalopram in the treatment of anxiety symptoms associated with depressionDepression and Anxiety, 2006
- Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*DPsychological Medicine, 2004
- Gepirone Extended-Release Treatment of Anxious DepressionThe Journal of Clinical Psychiatry, 2004
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959